Human kallikrein-related peptidase 12 (KLK12) splice variants discriminate benign from cancerous breast tumors

Clin Biochem. 2018 Aug:58:78-85. doi: 10.1016/j.clinbiochem.2018.05.017. Epub 2018 May 25.

Abstract

Objectives: As kallikrein-related peptidase 12 (KLK12) has been implicated in the cancer progression and alternative splicing plays significant role in this disease, the aim of this study was to examine the expression profile and the clinical impact of the KLK12 splice variants in breast cancer.

Design and methods: Total RNA was isolated and reverse transcripted from 141 tissues. Afterwards, quantitative real-time PCR were conducted, followed by the performance of the comparative CT (2-ΔΔCT) method for relative quantification, whilst their correlation with the clinicopathological features of breast malignancies were assessed by statistical analysis.

Results: Both KLK12sv1/2 and KLK12sv3 showed higher expression in non-cancerous than in cancerous samples. KLKsv1/2 (P = 0.001) upregulated and KLK12sv3 (P < 0.001) downregulated in the malignant compared to the benign tumors and their discriminative ability was verified by ROC curve analysis. Moreover, KLK12sv3 was associated with grade (P = 0.012) and hormonal receptor status (P = 0.001). Furthermore, Kaplan-Meier and Cox regression analyses showed that patients with positive KLK12sv1/2 and KLK12sv3 levels presented a significantly longer disease-free survival (P = 0.014 and P = 0.013, respectively) and overall survival (P = 0.062 and P = 0.004, respectively).

Conclusions: Our results demonstrate the discriminative value of KLK12sv1/2 and KLK12sv3 between benign and malignant breast tumors as well as their potential favorable prognostic significance in breast adenocarcinoma.

Keywords: KLK12sv1/2; KLK12sv3; Mammary malignancy; Molecular tumor markers; Prognostic biomarkers; Reverse-transcription real-time quantitative polymerase chain reaction (RT-qPCR).

MeSH terms

  • Adenocarcinoma* / classification
  • Adenocarcinoma* / enzymology
  • Adenocarcinoma* / genetics
  • Adenocarcinoma* / mortality
  • Adult
  • Aged
  • Aged, 80 and over
  • Alternative Splicing*
  • Breast Neoplasms* / classification
  • Breast Neoplasms* / enzymology
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / mortality
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Enzymologic*
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Kallikreins / biosynthesis*
  • Kallikreins / genetics
  • Middle Aged
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Survival Rate

Substances

  • Neoplasm Proteins
  • KLK12 protein, human
  • Kallikreins